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Abstract
Background: Lentiviral vectors with broad tropism are one of the most promising gene delivery
systems capable of efficiently delivering genes of interest into both dividing and non-dividing cells
while maintaining long-term transgene expression. However, there are needs for developing
lentiviral vectors with the capability to deliver genes to specific cell types, thus reducing the "off-
target" effect of gene therapy. In the present study, we investigated the possibility of engineering
the fusion-active domain of a fusogenic molecule (FM) with the aim to improve targeted
transduction of lentiviral vectors co-displaying an anti-CD20 antibody (αCD20) and a FM.
Results: Specific mutations were introduced into the fusion domain of a binding-deficient Sindbis
virus glycoprotein to generate several mutant FMs. Lentiviral vectors incorporated with αCD20
and one of the engineered FMs were successfully produced and demonstrated to be able to
preferentially deliver genes to CD-20-expressing cells. Lentiviral vectors bearing engineered FMs
exhibited 8 to 17-fold enhanced transduction towards target cells as compared to the parental FM.
Different levels of enhancement were observed for the different engineered FMs. A pH-dependent
study of vector transduction showed that the broader pH range of the engineered FM is a possible
mechanism for the resulted increase in transduction efficiency.
Conclusion: The fusion domain of Sindbis virus glycoprotein is amenable for engineering and the
engineered proteins provide elevated capacity to mediate lentiviral vectors for targeted
transduction. Our data suggests that application of such an engineering strategy can optimize the
two-molecular targeting method of lentiviral vectors for gene delivery to predetermined cells.
Background
Viral gene delivery using retroviral vectors remains one of
the most promising techniques for gene therapy [1,2]. For
certain situations, one may prefer to deliver genes in a cell-
type specific manner, alleviating the "off-target" effect
[3,4]. Thus, many investigations have focused on how to
engineer retroviral vectors into targeted gene delivery
vehicles [4]. Significant works have been reported in
which the viral envelope glycoprotein is engineered to
redirect the host tropism by either inserting a targeting lig-
and or a single-chain antibody [3,5-11]. Another popular
strategy for achieving targeted transduction is directing
the viral vectors to the target cell by an adaptor molecule
[3,12-18]. Although these approaches can generate vec-
tors that recognize specific cells, the modification and
binding interference introduced to the envelope protein
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unavoidably affects the performance of the glycoprotein
to mediate transduction [3,19].
Lentiviral vectors, a subfamily of retroviral vectors, have
been widely studied for the purpose of gene delivery
because of their ability to transduce both dividing and
non-dividing cells [20]. Like other retroviral vectors, their
integration ability has enabled the vector-transduced cells
to maintain a long-term stable expression of transgenes
[1,2]. Recently, we developed a novel method to engineer
lentiviral vectors that transduce specific cell types by
breaking up the binding and fusion functions of the enve-
lope protein into two distinct proteins [21]. Instead of
pseudotyping lentiviral vectors with a modified viral enve-
lope protein, our lentiviral vectors co-display a targeting
antibody and a fusogenic molecule (FM) on the same viral
vector surface. Based on the molecular recognition, the
targeting antibody will direct lentiviral vectors to the spe-
cific cell type. The binding between the antibody and the
cognate cellular antigen will induce endocytosis resulting
in the transport of lentiviral vectors into the endosomal
compartment. Once inside the endosome, the FM will
undergo a conformation change in response to the drop
in pH, thereby releasing the viral core into the cytosol
[22].
We previously demonstrated that a binding defective ver-
sion of the alphavirus Sindbis glycoprotein was able to
envelope lentiviral vectors to mediate fusion of viral
membrane and endosomal membrane, a critical step for
transduction [21,22]. Kielian and co-workers had studied
the cholesterol dependency of the Sindbis virus and
reported several versions of the Sindbis virus glycoprotein
that were less dependent on cholesterol for transduction
[23]. We report herein that engineering the fusion domain
of the binding defective Sindbis glycoprotein can enhance
fusion function of this protein to pair with an anti-CD20
antibody (αCD20), hence mediating targeted transduc-
tion of lentiviral vectors to CD20-expressing cells. The cel-
lular antigen used in this study is the CD20 protein,
whose expression is B cell specific [24]. It has been shown
that 90% of non-Hodgkin's lymphomas are CD20-posi-
tive [25-27]. CD20 is not usually expressed on either pre-
cursor B lymphoid cells or the majority of plasma B cells
[27]. Thus, this stage-specific expression pattern makes
CD20 an ideal target for therapies against B cell malig-
nancy.
Results
Generation of pH-dependent FMs
We previously demonstrated that cell-specific targeted
transduction can be achieved by lentiviral vectors envel-
oped with αCD20 and a FM [21]. The FM used in that
study was a mutant viral glycoprotein derived from the
Sindbis virus. The Sindbis envelope glycoprotein consists
of two domains; E1 is responsible for mediating the
fusion between the virus and target cell and E2 is respon-
sible for directing the binding of the virus to the cellular
antigen on the target cell surface [28]. Chen and co-work-
ers reported a fusion-competent, but binding-deficient
form of the Sindbis envelope glycoprotein which was gen-
erated by inserting a ZZ binding domain into the E2
region of the envelope protein [13,14]. We further modi-
fied this binding-deficient envelope protein by replacing
the ZZ binding domain with a HA tag; the resulting pro-
tein was designated SINmu [21]. In addition, Kielian and
co-workers have previously shown that a mutation on E1,
at region 266, of the Sindbis virus envelope protein results
in viruses that were less dependent on cholesterol for
transduction [23]. Their work identified three distinct
mutants with enhanced efficiency to transduce choles-
terol-depleted cells [23]. We reasoned that incorporation
of these mutations into SINmu might endow new FMs
with enhanced efficiency to induce fusion of antibody-
displaying lentiviral vectors to accomplish targeted trans-
duction. To test this hypothesis, we generated three FMs
designated as SGN, SGM and AGM (Fig. 1). These FMs dif-
fered from the parental FM (SINmu) by three amino acids
at region 226 of the E1 protein.
Production of recombinant lentiviral vectors
To evaluate the targeting activity of these engineered FMs,
we employed a transient transfection protocol to produce
lentiviral vectors enveloped with αCD20 and a specific
FM [29]. We co-transfected 293T cells with FUGW, the
self-inactivating lentiviral transfer construct that is derived
from HIV-1, which contains an internal human ubiquitin-
C promoter driving the expression of GFP reporter gene
(Fig. 1) [30]. In addition to FUGW, we supplied the lenti-
viral packaging plasmids, the αCD20 construct, the anti-
body accessory protein construct, and the plasmid
encoding the FM (SINmu, SGN, SGM, or AGM). The
αCD20 system has been previously established in our lab-
oratory and has been shown to display on the surface of
lentiviral vectors for targeted transduction of CD20-
expressing cells [21]. Therefore, we used this as a model
system for testing FMs. Antibody accessory proteins (Igα
and Igβ) were required for functional expression of the
antibody onto the surface of producing cells for its subse-
quent incorporation into the viral vector (Fig. 1). As a
non-targeting control, a transfection was done to prepare
a vector pseudotyped with VSVG since it has fairly broad
specificity and can transduce a variety of cell types [31].
Negative controls included vectors bearing a FM and an
antibody (Ab) that is blind to CD20 antigen and the vec-
tor bearing αCD20 only. Two days after transfection,
expressions of GFP, αCD20 and FM were analyzed by flow
cytometry. Virtually all of the transfected, virus-producing
293T cells expressed GFP which was encoded in FUGW
(Fig. 2a). Among these GFP-positive cells, approximatelyJournal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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21–31% of them expressed both αCD20 and a FM
(FUGW+αCD20+FM, Fig. 2b, top left). The viral vectors
produced by these transfections were designated FUGW/
αCD20+FM. A similar percentage of GFP-positive cells
were observed to express both a FM and Ab
(FUGW+Ab+FM, Fig. 2b, bottom left) and the corre-
sponding viral vectors were designated FUGW/Ab+FM. As
expected, the FM signals were not detected on cells trans-
fected to produce αCD20-bearing, but FM-lacking,
FUGW/αCD20 vector (FUGW+αCD20, Fig. 2b, top right),
and no signals of the FM and the αCD20 were seen on
cells producing the FUGW/VSVG vector (FUGW+VSVG,
Fig. 2b, bottom right). In addition, it appeared from the
expression pattern of FM-transfected cells that the expres-
sion level of the four FMs were similar, suggesting that
they could be incorporated into the surface of lentiviral
vectors with similar efficiency.
Co-incorporation of the αCD20 and the FM on lentiviral 
vectors
In order for our targeting system to work, lentiviral vectors
must be enveloped with both αCD20 for binding, and a
FM for fusion. We employed a confocal imaging method
to analyze the co-incorporation of the αCD20 and the FM.
The target cells were incubated with viral vectors at 4°C
for 1 hour, followed by sequential staining of the FM
(blue color) and the αCD20 (red color). To label the core
of the vectors, we adapted a previously reported method
to synthesize viral vectors encapsulated with a protein
(GFP-Vpr) consisting of GFP fused with viral protein R
(Vpr) [32]. It has been shown that the provision of GFP-
Vpr in trans during transfection can allow the fluorescent
protein to be incorporated into the core of HIV-based len-
tiviral vectors through the interaction between Vpr and
the P6 region of the HIV gag protein [32]. We harvested
GFP-Vpr-tagged lentiviral vectors bearing αCD20 and
SINmu and incubated them with 293T/CD20 cells at 4°C
for 1 hour. After extensive washing, the treated cells were
subjected to immuno-fluorescence staining and imaging.
GFP-labeled signals were detected on the surface of 293T/
CD20 cells and their signals were co-localized with signals
for both αCD20 and SINmu (Fig. 3a, top), while no fluo-
rescence signals were obtained for 293T cells lacking the
expression of CD20 (Fig. 3a, bottom). The co-localization
of GFP, αCD20 and SINmu suggested that the cells can
produce lentiviral vectors displaying both αCD20 and a
FM in a single virion. Similar results were also observed
for vectors bearing the other type of FMs (SGN, SGM, or
AGM) (data not shown).
We conducted flow cytometry analysis of cells incubated
with viral vectors to further examine their surface proper-
ties. Various vectors (FUGW/αCD20+FM) were allowed
to bind to 293T/CD20 target cells at 4°C for 1 hour, after
which the FM was stained and analyzed. Only the vectors
bearing both αCD20 and a FM could bind to 293T/CD20
cells and be detected by using an antibody against the FM.
Therefore, flow cytometry signals can indicate the pres-
ence of both αCD20 and a FM on the same viral surface.
As shown in Fig. 3(b), no detectable FM signals were seen
when the 293T cells were incubated with either FUGW/
αCD20+FM or FUGW/Ab+FM vectors, indicating that the
lentiviral vectors were unable to bind to 293T cells lacking
the expression of CD20. When FUGW/Ab+FM were incu-
bated with 293T/CD20 cells, no signals were detected for
the FM (Fig. 3b). Clear signals were obtained when 293T/
CD20 and FUGW/αCD20+FM were incubated together
(Fig. 3b). This result confirmed that cell-virus binding was
Schematic representation of key constructs in this study  encoding the FM derived from the Sindbis virus glycoprotein,  lentiviral transfer vector FUGW, membrane-bound human/ mouse chimeric antibody against CD20 (αCD20), and acces- sory proteins for surface expression of antibody (Igαβ) Figure 1
Schematic representation of key constructs in this 
study encoding the FM derived from the Sindbis virus 
glycoprotein, lentiviral transfer vector FUGW, mem-
brane-bound human/mouse chimeric antibody 
against CD20 (αCD20), and accessory proteins for 
surface expression of antibody (Igαβ). CMV: human 
cytomegalovirus immediate-early gene promoter; E3: leader 
peptide of Sindbis virus glycoprotein; E1: E1 protein of the 
Sindbis virus glycoprotein for mediating fusion; E2: E2 protein 
of the Sindbis virus glycoprotein for binding to viral receptor; 
HA tag: 10-amino acid epitope hemagglutinin sequences 
(MYPYDVPDYA); Ubi: human ubiquitin-C promoter; GFP: 
green fluorescent protein; WPRE: woodchuck regulatory ele-
ment; LTR: long-terminal repeat; ΔU3: U3 region with dele-
tion to disable the transcriptional activity of integrated viral 
LTR promoter; EF1α: human elongation factor 1α promoter; 
αCD20κ and αCD20λ: light chain and heavy chain of human/
mouse chimeric antibody against CD20; TM: human antibody 
transmembrane domain; Igα and Igβ: human antibody acces-
sory proteins Igα and Igβ. For the FM constructs (SINmu, 
SGN, SGM and AGM), the amino acid sequences at E1 226 
region are shown. The sequence starts at amino acid 225 and 
ends with amino acid 234 of the wild-type E1 protein. Spe-
cific amino acids involved in generating new FMs are shown 
underlined in bold.Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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Co-expression of an antibody and a FM on the surface of transfected vector producing cells Figure 2
Co-expression of an antibody and a FM on the surface of transfected vector producing cells. 293T cells were tran-
siently transfected with plasmids FUGW, pαCD20, pIgαβ, pFM, along with other standard packing plasmids to produce tar-
geted FUGW/αCD20+FM vectors. The plasmid pAb was used in transfection to generate control vectors FUGW/Ab+FM. The 
transfection without FM plasmid was performed to generate the control vector FUGW/αCD20. The transfection with the 
standard envelope plasmid encoding VSVG was conducted to generate the non-targeting control vector FUGW/VSVG. (a) 
FACS analysis of GFP expression in vector producing cells. Solid line, analysis on transfected 293T cells; shaded area, analysis 
on 293T cells (as control) (b) Gating on GFP-positive cells, co-expression of an antibody and a FM is shown. Expression of an 
antibody and a FM were detected by using anti-human IgG antibody and anti-HA antibody, respectively.Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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attributed to the interaction between the αCD20 and
CD20, and both a FM and αCD20 can be incorporated
onto the same viral surface.
Targeted transduction of lentiviral vectors to CD20-
positive cell line
We then investigated how lentiviral vectors bearing differ-
ent FMs would transduce cells by using 293T/CD20 as the
target cell line, and the 293T parental cell line as the neg-
ative control. Six days post-transduction, cells were ana-
lyzed by flow cytometry. To quantify the difference of our
targeted transduction system, we utilized a metric that
incorporates both the efficiency and magnitude of the
GFP signals detected from the transduced cells [33]. The
transduction magnitude was obtained by the mean fluo-
rescence intensity (MFI) of the transduced cells. By multi-
plying the MFI by transduction efficiency, we derived a
metric termed integrated MFI (iMFI) that reflects the total
intensity of the GFP signals from the virus transduced
cells. As indicated in Fig. 4(a), FUGW/αCD20+AGM dis-
played the highest iMFI in the target cells (293T/CD20),
followed by FUGW/αCD20+SGM, FUGW/αCD20+SGN,
and FUGW/αCD20+SINmu. When the same set of viral
vectors were used to transduce the non-target cells (293T),
much lower iMFI signals were detected. The specific trans-
duction titers of these viral vectors against 293T and 293T/
CD20 cells were measured in Fig. 4(b); 8-17-fold increase
of preferential transduction of CD20-expressing cells was
achieved, depending on which FM was used (Fig. 4b). To
confirm that the specific transduction was mediated by
the incorporated antibody on the vector surface, we made
control vectors bearing a FM and Ab. Spin-transduction of
these vectors to 293T/CD20 and 293T cells showed low
iMFI signals (Fig. 4a). In addition, to eliminate the possi-
bility that the difference was due to a variance in viral pro-
duction from the producing cells, we performed an
enzyme linked immunosorbent assay (ELISA) to detect
the p24 levels in the viral supernatants. As indicated in
Fig. 4(c), the p24 levels between the different lentiviral
vectors were in the similar range. When comparing the
ability of various FMs to mediate transduction, the FM
with higher efficiency for targeted transduction would
always result in higher background transduction.
pH Dependence of various FMs
Our transduction experiment clearly showed the impor-
tant role of FMs in determining the overall vector infectiv-
ity and that the newly engineered FMs exhibited improved
ability to induce targeted transduction as compared to
original FM (SINmu) (Fig. 4). We designed an experiment
to investigate the possible underlying mechanism respon-
sible for their differences. Lentiviral vectors, FUGW/
αCD20+SINmu, FUGW/αCD20+SGN, FUGW/
αCD20+SGM, and FUGW/αCD20+AGM, were incubated
with 293T/CD20 cells in the absence or presence of a
graded concentration of ammonium chloride (NH4Cl);
NH4Cl is known to be able to neutralize the acidic endo-
somal environment [34]. The changes in transduction
were measured by flow cytometry. As shown in Fig. 5(a),
the four vectors displaying various FMs behaved differ-
ently in response to different concentration of NH4Cl.
FUGW/αCD20+SINmu was the most sensitive to the neu-
tralization treatment and transduction efficiency dropped
the fastest as a result of the changes in pH environment,
followed by FUGW/αCD20+SGN, FUGW/αCD20+SGM,
and FUGW/αCD20+AGM. It appeared that the engi-
neered vector that was more resistant to the NH4Cl treat-
ment could transduce target cells with a higher efficiency.
Antibody directed targeted transduction
To confirm that the targeted transduction was triggered by
the specific interaction between the antibody and the cog-
nate antigen, we performed an antibody competition
assay. Lentiviral vector, FUGW/αCD20+SGN was incu-
bated with 293T/CD20 cells in the presence of various
concentration of either soluble αCD20 antibody or an
isotype control (Fig. 5b). We found that the targeted trans-
duction efficiency decreased as the concentration of solu-
ble αCD20 antibody increased. When the isotype control
was used, no decrease in transduction efficiency was
observed. This suggested that the soluble αCD20 com-
peted with the targeted lentiviral vector leading to a
decreased uptake of the vectors.
Targeted transduction of lentiviral vectors to 
unfractionated primary B cells
One of the advantages of using targeted vectors is their
potential ability to transduce specific cell types in a mixed
population without the need to isolate the target cells. We
tested whether our targeted vectors with engineered FMs
can specifically transduce primary B cells in an unfraction-
ated primary cell population. One million of fresh,
unfractionated human peripheral blood mononuclear
cells (PBMC) were transduced twice with concentrated
FUGW/αCD20+FM (2.5 × 106 TU), or FUGW/VSVG (25 ×
106 TU). The cells were analyzed by flow cytometry 2 days
post-transduction. As shown in Fig. 6(a), transduction of
bulk PBMC populations with targeted vectors resulted in
specific modification of CD20-positive PBMC, whereas
no GFP signals were detected in CD20-negative cells. In
the control experiment where FUGW/VSVG was used for
transducing bulk PBMC populations, GFP signals were
detected in both CD20-positive and CD20-negative cells
and a higher iMFI signal was detected in the CD20-nega-
tive PBMC as compared to CD20-positive PBMC. Quanti-
fication of total expression intensity indicated that vector
FUGW/αCD20+AGM attributed the highest iMFI in the
CD20-positive PBMC, followed by FUGW/αCD20+SGM,
FUGW/αCD20+SIN, and FUGW/αCD20+SGN (Fig. 6b).
This was in good agreement with the specific transductionJournal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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Co-expression of αCD20 and a FM on the viral vector surface Figure 3
Co-expression of αCD20 and a FM on the viral vector surface. (a, left) Schematic diagrams to illustrate the interaction 
between αCD20 on the vector surface and CD20 on the cell surface, and the immuno-fluorescent staining scheme. (a, right) 
Acquired confocal images of labeled viral vector binding to cells. (b) FACS analysis of 293T or 293T/CD20 cells incubated with 
FUGW/αCD20+FM or FUGW/Ab+FM. The binding of virus to 293T/CD20 cells was detected by FACS staining with antibody 
against the FM. Solid line, analysis on cells incubated with indicated viral vectors; shaded area (control), analysis on cells without 
incubation with vectors.Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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against 293T/CD20 cells (Fig. 4b). The stable integration
of the GFP gene was confirmed by the genomic PCR anal-
ysis (data not shown).
Discussion
Lentiviral vectors pseudotyped with envelope glycopro-
tein from other genus of viruses, such as VSVG, have
shown to be able to genetically modify cells with great
efficiency and broad tropism [31]. However, certain appli-
cations may require using vector systems with cell-type
specificity [3,4]. Previous studies have shown that by
breaking up binding and fusion functions into αCD20
and a FM, targeted transduction can be accomplished
[21].
To test whether engineered FMs can improve vector target-
ing efficiency, we transduced 293T/CD20 with freshly col-
lected viral supernatants containing targeted lentiviral
vectors. Higher iMFI was observed when lentiviral vector,
FUGW/αCD20+AGM, was used, followed by a decrease in
iMFI in FUGW/αCD20+SGM, FUGW/αCD20+SGN, and
FUGW/αCD20+SINmu, respectively (Fig. 4a). These
results suggested that FUGW/αCD20+AGM was capable
of transducing target cells with higher efficiency and trans-
gene expression. However, some background levels of
transduction on non-target cells were observed. This is
likely resulted from the endocytosis induced by non-spe-
cific cellular receptors, although we did not observe obvi-
ous binding between targeting vectors and non-target cells
(Fig. 3b). We then set to examine whether such targeted
vectors can achieve similar results in PBMC. As shown in
Fig. 6(a), a similar trend was observed in that only CD20-
expressing PBMC were shown to be specifically trans-
duced by concentrated virus, whereas no transduction was
Transduction of engineered lentiviral vectors bearing both an antibody and FM to cell lines Figure 4
Transduction of engineered lentiviral vectors bearing both an antibody and FM to cell lines. 293T and 293T/CD20 
cells (2 × 105) were transduced with 2 ml of fresh viral vectors (FUGW/αCD20+FM, or FUGW/Ab+FM). Transduction of 
293T cells was included as control. (a) iMFI on 293T and 293T/CD20 cells transduced by the fresh viral vectors (FUGW/
αCD20+FM, or FUGW/Ab+FM). (b) Titers of fresh viral vectors (FUGW/αCD20+FM) on 293T and 293T/CD20 cells. (c) p24 
amount of fresh viral vectors (FUGW/αCD20+FM, FUGW/Ab+FM, and FUGW/VSVG)Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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Examination of addition of NH4Cl or solubleαCD20 on the targeted transduction results Figure 5
Examination of addition of NH4Cl or solubleαCD20 on the targeted transduction results. (a) NH4Cl was added 
into indicated viral supernatants during transduction for 8 hours, after which, the supernatants were replaced with fresh media. 
GFP expression was analyzed 3 days post-transduction. (b) Various amount of soluble αCD20 or isotype control were added 
into indicated viral supernatants during transduction for 8 hours, after which, the supernants were replaced with fresh media.Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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observed in the CD20-negative population. In the control
experiment, targeted lentiviral vectors were substituted
with a non-targeted vector, FUGW/VSVG, resulting in
detection of GFP in all cell types, regardless of CD20-
expression. It is known that FUGW/VSVG preferentially
transduce CD20-negative populations as compared to
CD20-positive population [35]. Furthermore, a higher
MOI was needed to achieve similar transduction effi-
ciency highlighting the advantage of targeting. In agree-
ment with previous cell line data, lentiviral vector, FUGW/
αCD20+AGM, was able to attribute the highest iMFI fol-
lowed by a decrease in iMFI in FUGW/αCD20+SGM,
FUGW/αCD20+SINmu, and FUGW/αCD20+SGN respec-
tively (Fig. 6a).
In order for our targeting system to work, the virus pro-
ducing cells must co-express both an antibody and a FM.
These vectors can then bind to the target cells based on the
recognition provided by the displayed antibody. When
adding a soluble antibody, transduction was inhibited
whereas addition of the isotype control had no effect on
transduction, indicating the binding requirement for tar-
geted transduction (Fig. 5b). After binding, these vectors
are endocytosed and transported to the endosomal com-
Targeted transduction of CD20-positive human primary B cells Figure 6
Targeted transduction of CD20-positive human primary B cells. (a) Fresh unfractionated human PBMCs (1 × 106) 
were spin-transduced twice with indicated vectors (FUGW/αCD20+FM, 2.5 × 106 TU, or FUGW/VSVG, 25 × 106 TU). 48 
hours later, cells were collected and analyzed by FACS (b) iMFI on fresh unfractionated human PBMCs transduced by the indi-
cated viral vectors (FUGW/αCD20+FM, and FUGW/VSVG).Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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partments. The changing of the pH environment within
the endosomes triggers the FM to alter its conformation,
leading to fusion between the endosomal membrane and
the viral membrane [22]. We believe these steps are
required for a successful targeted transduction and
employed various methods to investigate this targeted
transduction pathway. We first analyzed our virus produc-
ing cells for the display of the αCD20 and the FM by flow
cytometry (Fig. 2b), followed by confocal microscopic
imaging to confirm the co-incorporation of both mole-
cules in a single viral vector (Fig. 3a). GFP-Vpr fusion pro-
tein was used to label the viral core, while Alexa594-
conjugated and Cy5 antibodies were used to detect the
αCD20 and the FMs, respectively. Co-localization of all
three colors was observed, indicating that the viral vector
carried both the αCD20 and the FM. Cell-virus binding
assay was employed to evaluate whether the incorporated
antibody can provide the function to direct the viral vec-
tors to the target cells (Fig. 3b). As shown by both flow
cytometry analysis and confocal imaging, only the lentivi-
ral vectors bearing the targeting antibody were able to
bind to the target cells.
Since our engineered lentiviral vectors were enveloped
with αCD20 and a FM, it was conceivable that optimiza-
tion of these two proteins could potentially improve the
efficiency of this targeting system. Kielian and co-workers
generated three different mutants of the Sindbis virus glyc-
oprotein and found that these mutants could increase the
cholesterol independence of the Sindbis virus [23]. We
adapted these mutations into the original FM (SINmu) to
generate three new FMs (SGN, SGM, or AGM) (Fig. 1). We
found that these new FMs exhibited enhanced ability to
mediate lentiviral vectors to transduce the target cells. We
further analyzed the responsiveness of these FMs to acidic
neutralization. The neutralization assay with vectors bear-
ing different FMs revealed that the original FM (SINmu)
was the most sensitive to the pH change in the endosome,
as the infectivity of the vector bearing SINmu dropped the
fastest with respect to the ammonium chloride treatment.
The new FMs responded slower than that of SINmu to the
treatment, with AGM being the least pH-sensitive FM (Fig.
5a). These results were consistent with the transduction
assay, in which the vector bearing AGM had the highest
transduction titer (Fig. 4b).
The fusion mechanism for the Sindbis glycoprotein
involves a drop in pH that triggers a conformational
change in the E2 and E1 subunits that exposes the previ-
ously hidden E1 hydrophobic domain. The E1 domain
then interacts with cholesterol in the target membrane
which leads to the fusion of the viral and cellular mem-
branes [36]. Similar to the hemagglutinin glycoprotein of
the Influenza virus, mutations throughout the trimer
interface alter the pH threshold required for fusion by
either destabilizing the buried position of the fusion pep-
tide or by modifying salt bridges and hydrogen bonding
between trimer subunits [37]. We speculate that these
mutations may destabilize the fusion loop of the E1
domain which lowers the required activation energy
needed for fusion. Since the lentiviral vectors are required
to escape from the endosome in order to transduce the
host cells, the FM that is active throughout a wider pH
range could endow the corresponding lentiviral vector
with a larger window to escape from the degradation
pathway.
Conclusion
In summary, we have demonstrated in this report that tar-
geted transduction could be accomplished by enveloping
lentiviral vectors with αCD20 and a FM. One of the major
advantages of this system is the flexibility as the vectors
can be readily reengineered to target different cell type. As
shown in our previously published data, our system was
capable of targeting antigen specific immunoglobulins by
simply swapping the display antibody with an antigen
[38]. We are currently expanding our targeting strategy to
a variety of cell types including gp160 expressing cells. We
have also demonstrated that this targeted system is ame-
nable for further optimization to improve efficiency.
Although higher transduction efficiency could be
achieved by pairing the recognition antibody with novel
engineered FMs to improve fusion properties, it also led to
higher background transduction efficiency. We are cur-
rently studying our engineered FM in the hope that we
would gain some insight in the fusion process allowing us
to design a better FM capable of enhanced targeted trans-
duction with decreased background transduction. When
comparing findings from this paper to our previously
published data [39], it becomes apparent that a judicious
choice must be made when it comes to the FM, since FMs
behave differently under different settings. In the case of
gamma-retrovirus pseudotyped with FM, one FM showed
enhanced transduction whereas in the case of lentiviral
vector, multiple FMs showed enhanced efficiency. It is
noteworthy that one advantage of using lentiviral vector
as compared to gamma-retroviral vector lies in the ability
of lentiviral vectors to transduce non-dividing cells.
Methods
Construct preparation
The original FM, SINmu, was previously constructed in
our laboratory [21]. It was generated by replacing amino
acids 157KE158 with 157AA158 of the E2 protein of the
Sindbis virus glycoprotein. Additional deletion was per-
formed to remove amino acids 61–64 in the E3 protein of
the Sindbis virus glycoprotein. We also inserted a hemag-
glutinin epitope tag sequence (MYPYDVPDYA) between
amino acids 71 and 74 of the E2 proteins for detection
purpose (Fig. 1). Based on SINmu, we performed 4-Journal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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primer PCR-mutagenesis to generate mutants SGN, SGM,
and AGM. To construct SGN, a forward primer (BsiW1fw,
5'-GCC AGA TGA GTG AGG CGT ACG TCG AAT TGT
CAG C-3') and a backward primer (SGNbw, 5'-CAT GCA
CGT ACC GGA GGA AGG CTT GAG TAG CCT AAT GTC
TGT GCT G-3') were used to amplify the E1 domain con-
taining the BsiW1 site and the desired SGN mutations at
the E1 226 region. In parallel, a forward primer (SGNfw,
5'-AGC CTT CCT CCG GTA ACG TGC ATG TCC CGT ACA
CGC AGG CC-3') and a backward primer (Mfe1bw, 5'-
GCT GCA ATA AAC AAG TTA ACA ACA ACA ATT GCA
TTC ATT TTA TG-3') were used to amplify the E1 domain
containing the desired SGN mutations at the E1 226
region and Mfe1 site. The DNA products from these two
reactions were PCR-assembled using BsiW1fw and
Mfe1bw as the primer pair and cloned into pcDNA3 (Inv-
itrogen) to yield SGN. The similar PCR protocol was used
to generate mutant SGM and AGM, except that the prim-
ers SGNbw and SGNfw were replaced by (SGMbw, 5'-CAT
GCA CCA TAC CGG AGG AAG GCT TGA GTA GCC TAA
TGT CTG TGC TG-3') and (SGMfw, 5'-AGC CTT CCT CCG
GTA TGG TGC ATG TCC CGT ACA CGC AGG CC-3') for
construction of SGM, and by (AGMbw, 5'-CAT GCA CCA
TAC CGG CGG AAG GCT TGA GTA GCC TAA TGT CTG
TGC TG-3') and (AGMfw, 5'-AGC CTT CCG CCG GTA
TGG TGC ATG TCC CGT ACA CGC AGG CC-3') for con-
struction of AGM.
The construct encoding the membrane bound form of the
human/mouse chimeric antibody against human CD20
antigen (pαCD20) and the construct encoding the human
antibody accessory proteins Igα and Igβ (pIgαβ) were con-
structed previously in our laboratory [21]. Briefly, the
cDNAs of the human κ light chain constant region, and
the membrane bound human IgG1 constant chain region
were amplified and inserted downstream of the human
CMV and EF1α promoters, respectively, in the
pBudCD4.1 vector (Invitrogen). The light chain variable
region from the murine αCD20 was amplified from an
αCD20 hybridoma cell line (ATCC, Manassas, VA, HB-
9303) with (CD20Lvfw, 5'-CCC AAG CTT ATG GAA ACC
CCA GCG CAG CTT C-3') and (CD20Lvbw, 5'-CAG CCA
CCG TAC GTT TCA GCT CCA GCT TG-3') and inserted
directly upstream of the light chain constant region via
Hind3 and BsiW1 restriction sites. In parallel, the heavy
chain variable region was amplified with (CD20Hvfw, 5'-
GGA CTC GAG ATG GAG TTT GGG CTG AGC TG-3') and
(CD20Hvbw, 5'-GGT GCT AGC TGA AGA GAC GGT GAC
CGT G-3') and inserted directly upstream of the heavy
chain constant region via Xho1 and Nhe1 restriction sites.
The non-relevant antibody (Ab) used in this study, B12,
was kindly provided by the laboratory of Dr. Dennis Bur-
ton at the Scripps Research Institute [40]. The membrane
bound B12 antibody was constructed similarly to the
αCD20, except that (B12Lvfw, 5'-CCC AAG CTT ACC ATG
GGT GTG CCC ATC C-3') and (B12Lvbw, 5'-CAC CGT
ACG TTT CCT CTC CAG TTT GGT CCC-3') were used to
amplify the light chain variable region, and (B12Hvfw, 5'-
GGG ACC AAA CTC GAG AGG AAA CGT ACG GTG-3')
and (B12Hvbw, 5'-GGT GCT AGC TGA GCT CAC GAT
GAC CGT GG-3') were used to amplify the heavy chain
variable region. The HIV-1-based lentiviral transfer plas-
mid FUGW was constructed by the laboratory of Dr.
David Baltimore at the California Institute of Technology
[30].
Cell line construction
The 293T cell line was obtained from ATCC. The cell line
293T/CD20 was generated by stable transduction of vesic-
ular stomatitis virus glycoprotein (VSVG) enveloped len-
tiviral vector encoding the cDNA for the human CD20
protein.
Virus production
Recombinant lentiviral vectors were generated via the
standard calcium phosphate precipitation technique [29].
The vectors producing 293T cells were seeded in a 6-cm
culture dish with DMEM medium supplemented with
10% Fetal Bovine Serum (Sigma, St. Louis, MO), L-
glutamine (10 mL L-1), penicillin (100 units mL-1), and
streptomycin (100 units mL-1). After 16–18 hours, when
the confluency was about 80%, the seeded 293T cells were
transfected with plasmid DNAs. The packaging plasmids,
pMDLg/pRRE (2.5 μg) and pRSV-Rev (2.5 μg) [38], the
plasmids for surface display of αCD20, pαCD20 (2.5 μg)
and pIgαβ (2.5 μg), the plasmid encoding the FMs, pFM
(2.5 μg), and the lentiviral transfer plasmid FUGW (5 μg)
were mixed with calcium chloride and added drop-wise to
2× HBS solution with constant vortexing [41]. The lentivi-
ral vector FUGW/Ab+FM was produced similarly with the
exception that the plasmid encoding pAb was used
instead of pαCD20. Co-transfection of 293T cells with the
lentiviral transfer plasmid FUGW (5 μg), the packaging
plasmids pMDLg/pRRE (2.5 μg) and pRSV-Rev (2.5 μg),
and the envelope plasmid pVSVG (2.5 μg) was performed
to generate the lentiviral vector FUGW/VSVG. Transfected
cells were replenished with pre-warmed fresh media 4
hours post-transfection. 48 hours later, viral supernatants
were harvested, and filtered through a 0.45 μm pore size
filter (Nalgene, Rochester, NY).
Fluorescent labeling
GFP-Vpr-labeled lentiviral vectors were produced by co-
transfecting 293T cells with the plasmid encoding GFP-
Vpr [22] in addition to the plasmids used in generation of
corresponding lentiviral vectors. For imaging cell-virus
binding, 5 × 105 cells were seeded onto a 35 mm glass-bot-
tom culture dish (MatTek Corporation) and grown at
37°C overnight. The seeded cells were rinsed with cold
PBS twice and incubated with concentrated viral vectorsJournal of Biological Engineering 2009, 3:8 http://www.jbioleng.org/content/3/1/8
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for 1 hour at 4°C to allow for binding. Cells were washed
with cold PBS to remove unbound viral vectors, fixed for
10 minutes on ice using 4% formaldehyde, and then
immunostained by Alexa594-conjugated anti-human IgG
(Molecular Probes) and biotin-conjugated anti-HA anti-
body (Miltenyi Biotec Inc.), followed by a secondary
staining with Cy5-conjugated streptavidin (Zymed Labo-
ratories). The images were acquired with a Zeiss LSM-510
laser scanning confocal microscope (Carl Zeiss, Thorn-
wood, NY) using a plan-apochromat 63×/1.4 oil immer-
sion objective. The images were processed using the LSM
510 software version 3.2 SP2.
FACS analysis of cell-virus binding
0.5 million cells (293T or 293T/CD20) were incubated
with 2 mL of various lentiviral vectors at 4°C for 1 hour.
Cell-virus complexes were then washed with 4 mL of cold
PBS and spun down at 2,000 rpm for 5 minutes. Cell-virus
complexes were then stained with anti-HA antibody to
detect the presence of the FM on the lentiviral vectors
bound to the target cells. After staining, cells-virus com-
plexes were analyzed by flow cytometry (BD Bioscience)
to measure the binding.
p24 analysis of lentivral vectors
Various lentiviral vectors (10 μL, fresh supernatant) were
lysed with 90 μL of 10% Triton-X 100 in PBS and the p24
levels were measured by a p24 antigen capture enzyme
linked immunosorbent assay (ELISA) kit (ImmunoDiag-
nostics, Woburn, MA)
Targeted transduction
Various lentiviral vectors (2 mL, fresh supernatant) were
added to 0.2 million cells (293T or 293T/CD20) plated in
a 24-well culture dish and spin-transduced for 90 minutes
at 2,500 rpm and 25°C. The medium was then removed
and replenished with 2 mL fresh media. Treated cells were
incubated for 6 days at 37°C and 5% CO2. The percentage
of GFP expression was determined by flow cytometry
analysis. The titer was calculated based on the GFP expres-
sion in the viral dilution range where the percentage of
GFP-positive cells linearly corresponded to the volume of
virus.
NH4Cl neutralizing assay
293T/CD20 cells (0.2 million) were incubated with lenti-
viral vectors (FUGW/αCD20+FM) in the presence of vari-
ous amounts of NH4Cl in a 24-well culture dish at 37°C
and 5% CO2 for 8 hours. The medium was then removed
and replenished with fresh medium and incubated for an
additional 3 days prior to flow cytometry analysis.
Antibody competition assay
293T/CD20 cells (0.2 million) were incubate with lentivi-
ral vectors (FUGW/αCD20/SGN) in the presence of vari-
ous amounts of either soluble αCD20 or isotype control
in a 24-well culture dish at 37°C and 5% CO2 for 8 hours.
The medium was then removed and replenished with
fresh medium and incubated for an additional 3 days
prior to flow cytometry analysis.
Targeted transduction of unfractioned PBMC
Lentiviral vectors (FUGW/αCD20+FM) were generated
and concentrated by ultracentrifugation (Optima L-90K
Ultracentrifuge, Beckman Coulter, Fullerton, CA) at
25,000 rpm for 90 minutes and resuspended in 100 μl
cold PBS after overnight incubation. The concentrated
vectors (2.5 × 106 transduction units (TU) of the targeted
lentiviral vectors and 25 × 106 of the VSVG pseudotyped
lentiviral vector) and 1 million unfractioned PBMC were
spin-transduced for 90 minutes at 2,500 rpm and 25°C.
The medium was then removed and replenished with 1
mL fresh medium. LPS (50 μg ml-1) was then added to
support the survival and growth of B cells. Treated cells
were collected 48 hours post-transduction and stained
with anti-human CD20 antibody. Flow cytometry was
employed to determine the efficiency of targeted trans-
duction.
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